Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | GOT1 | P17174 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925250 | 0.87 | GOT1 (0.36) | GAABRD4BRD2GOT1HPGDS | |
| SCHEMBL12286232 | 0.85 | GPR52 (0.33) | GAADHFRGOT1GPR52PHGDH | |
| SCHEMBL806554 | 0.84 | GOT1 (0.36) | GAABRD4BRD2DHFRGOT1 | |
| SCHEMBL14933295 | 0.84 | BRD4 (0.38) | GAABRD4BRD2DHFRGOT1 | |
| SCHEMBL13983476 | 0.77 | HSP90AA1 (0.53) | — | |
| SCHEMBL806553 | 0.76 | HSP90AA1 (0.40) | GAADHFRGOT1HPGDS | |
| SCHEMBL13983147 | 0.76 | HSP90AA1 (0.43) | GAAGFERKMT2A | |
| SCHEMBL12180125 | 0.76 | GOT1 (0.39) | GAABRD4BRD2GOT1HPGDS | |
| SCHEMBL2596691 | 0.76 | DAO (0.33) | GAASYK | |
| SCHEMBL806551 | 0.71 | HSP90AA1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012037072-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011146803-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2008153730-A2 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | SYNTA PHARMACEUTICALS CORP. (US) | 2008-12-18 | — | — | WO | disclosed |